Ace:
News
Day care and treatment
The United States approves the use of Aducanumab: a treatment for Alzheimer's disease
11/06/2021
Ace Alzheimer Center Barcelona participated in Biogen's clinical trial for the drug Aducanumab. During the clinical trial, we were the sixth center that was able to include the most people in the study worldwide and the first in Europe.
The United States approves the use of Aducanumab: a treatment for Alzheimer's disease
11/06/2021Day care and treatment
Ace Alzheimer Center Barcelona participated in Biogen's clinical trial for the drug Aducanumab. During the clinical trial, we were the sixth center that was able to include the most people in the study worldwide and the first in Europe.
Fundació Mir-Puig, collaborator of Ace Alzheimer Center Barcelona
10/06/2021SCR
The charity based in Barcelona signs a collaboration agreement to offer financial support to the research projects that Ace develops.
The webinar “Molecular Biomarkers of Neurodegeneration” stands out for the high participation of attendees
01/06/2021News
More than 165 attendees of 18 different nationalities gathered to hear the latest news on molecular biomarkers in neurodegenerative diseases
Registration open for the webinar “Molecular biomarkers of neurodegeneration”
11/05/2021News
Next Friday, May 28th, the webinar "Molecular Biomarkers of Neurodegeneration" will be dedicated to a specific area of the diagnostic and pathological process of neurodegenerative diseases by trying to update and discuss the different molecular biomarkers
Consanguinity and Alzheimer
05/05/2021News
The prestigious publication Translational Psychiatry has published a new study of the GR@ACE project that concludes for the first time that the consanguinity is a risk factor for Alzheimer’s